Proportional change of enrolled patients in each geographical region between 2000 and 2006 MARCH 2008 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM.

Slides:



Advertisements
Similar presentations
SCOLA. SCOLA is a content acquirer/provider. SCOLA is a content acquirer/provider. We import and re-transmit electronic and hard media from 105 countries.
Advertisements

® Students 9,866,143 Students 9,866,143 Students 382,637Volunteers.
© 2013 Ipsos. All rights reserved. Contains Ipsos' Confidential and Proprietary information and may not be disclosed or reproduced without the prior written.
© 2013 Ipsos. All rights reserved. Contains Ipsos' Confidential and Proprietary information and may not be disclosed or reproduced without the prior written.
Roaming offers May 2014.
1 d 2 w Award programme Example: NH Hoteles Launch March 2010 All users are entitled to a certificate as part of the PR/ marketing programme. Recently.
The Freedom to Publish Opinion Poll Results June 15, 2012 Presented by Dr. Robert Chung Director of Public Opinion Programme, The University of Hong Kong.
© 2012 Ipsos. All rights reserved. Contains Ipsos' Confidential and Proprietary information and may not be disclosed or reproduced without the prior written.
Palestine: A Market for the Patient December 2012 “Good Things Come to Those Who Wait”
Build /16/2017 © 2015 Microsoft Corporation. All rights reserved. MICROSOFT MAKES NO WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, AS TO THE INFORMATION.
© Lloyd’s Regional Watch Content Guide CLICK ANY BOX AMERICAS IMEA EUROPE ASIA PACIFIC.
Ipsos Training Center ITC Annual Report – /08/20151 Campus Report 2011 Ipsos Training Center.
WINDOWS AZURE Mark Brown Senior Product Marketing Manager – Community & Web Windows Azure
Windows Azure Joseph Landes General Manager, DPE Microsoft India
ISBN What The Numbers Mean Exactly. The prefix element. The registration group identifier. The registrant and the publisher element. The publication element.
Anticipated 2008 Generic Launches JULY 2008 David Harding, API Intelligence, Thomson Reuters Source: FDA, NEWPORT HORIZON PREMIUM TM © THOMSON REUTERS.
What can we learn from the available data? Mike Palmedo June 9, 2014.
Windows Azure Global Footprint video Inside a Datacenter 
MESSAGING IN THE MEDIA TOP 10 DRUGS BASED ON CREDIBILITY INDEX IN THE LITERATURE JOHN KNAPP, DIRECTOR OF ANALYTICS MAY 2009 Your use of these materials.
Windows Azure Inside a Datacenter  video 
WELCOME TO THE MAP LIBRARY.  The map library provides you with a range of ready-to-use maps that can be used in your PowerPoint presentations.  The.
Therapeutic area breakdown of lead projects in development for first launch in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM ©
Paragraph IV Patent Challenges – As of July 1, 2008 JULY 2008 David Harding, API Intelligence, Thomson Reuters Source: FDA, NEWPORT HORIZON PREMIUM TM.
Global MAX Welcome to the world of…. About us We take pleasure in inviting you to become a member of Global MAX. We have two objectives: 1 st to provide.
Proportion of biotech-derived active substances in development for first launch 31st December APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
Statistics Project Wendy Kim & Tina Shin.  What is the most visited country in the world?
Proportion of total R&D expenditure by therapeutic area in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS Your.
Global R&D expenditure, development times, global pharmaceutical sales and new molecular entity output MARCH 2008 SOURCE: CMR INTERNATIONAL.
2005/2006 Expenditure on biotech derived entities had remained constant APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS.
Number of pharmaceutical patent applications and granted patents for 5 major patent issuing authorities JUNE 2008 SOURCE: DERWENT WORLD PATENTS.
Regulatory approval times between submission and marketing authorization approval APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM.
Availability of High-Quality API for India, China and Rest of World MARCH 2008 David Harding, API Intelligence, Thomson Reuters Source: NEWPORT HORIZON.
Allocation of R&D expenditure in 2005 between chemical entity and biological or biotech active substances APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
Copyright © 2007 Rockwell Automation, Inc. All rights reserved. Insert Photo Here RSLogix 5000 with FactoryTalk Activation Grace Period.
N= 14,210 * Includes English Learners (ELs) in Philadelphia School District schools as of February 15,2017. Incluye estudiantes de inglés como segundo.
World Development Chart 2004
Certification CS-100/ CSE-200 /CSC-1
Fifth Global Forum on Reinventing Government
Bedsonline is a market leading online accommodation and travel extras provider
Vodafone Roaming Charges
**The percentage share held in gold of total foreign reserves, as calculated by the World Gold Council. The value of gold holdings is calculated using.
Trade Patterns U.S. Imports
BIOLOGY / CHEMISTRY CITATIONS GROWTH
Presented by World Sleep Society
United Arab Emirates**
Economic Exports.
Electrification Products
Campus Report Q Ipsos Training Center.
Locations where Black Panther was released in the theaters in 2018.
Name the world flag… Bell Ringer Activity
Messaging in the Media TOP 10 AUDIENCES BY THERAPY AREA
Sourcing. Costs. HARDWARE + SERVICE
Eastern Europe, Russia and Middle and South America
2006 Revenue continued to depend on a relatively small number of products APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS.
, R&D expenditure showed 6% growth annually
2002–2006 Mid and Other sized companies continued to launch the majority of NMEs APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON.
Red Plans December 2018.
Proportion of total R&D expenditure on alliances or joint ventures by stage of R&D in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM.
NME/NAS launches in 2005/6 APRIL 2007
% of the projects in development in the leading therapeutic areas were considered to have a novel mode of action APRIL 2007 SOURCE: CMR INTERNATIONAL.
**The percentage share held in gold of total foreign reserves, as calculated by the World Gold Council. The value of gold holdings is calculated using.
Pipeline size of Major companies had grown at a steadier rate than that of smaller companies APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
Development time for new molecular entities first launched onto the world market between MARCH 2008 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS.
Cycle times decreased in larger but not smaller, companies
IBM's Geographical Structure and where IBM Global Financing has clients IBM Global Financing, the world's largest IT captive financier, has a total asset.
Disclaimer This document contains data provided to WHO by member states. Note that some member states only provide aggregate data to WHO, and for these,
Proportion of total R&D expenditure by function in 2005
IPO and Foreign Listing on Istanbul Stock Exchange Çağatay Duruk Director Foreign Securities Market.
People.
Electrification business
Presentation transcript:

Proportional change of enrolled patients in each geographical region between 2000 and 2006 MARCH 2008 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS Your use of these materials is subject to the terms and conditions hereof. Please read the disclaimer carefully before using these materials.

Proportional change of enrolled patients in each geographical region between 2000 and 2006 Chapter 6 Regional comparisons Figure 6.4 Global patient enrolment 2000 vs 2006 Europe Core Europe Non-Core EU Accession 2006 14% 13% 7% 2000 21% 8% 4% ME & Africa 2% 2000 41% 2006 39% North America 2000 2% 2006 7% SE Asia & W Pacific Key message Comparing 2006 with the start of the decade, the proportion of patients enrolled in the 5 major European markets has declined by one third, with a modest decrease also observed in North America. The decline has been counterbalanced by increases in the number enrolled from the emerging markets and other European countries. Methodology This analysis compares the proportion of enrolled patients in each geographical region in 200 with 2006. Studies were included where enrolment was completed in the year ranges specified and patient data by region were available. Data from 23 companies providing data for all years. Key Definitions Europe Core countries: Includes France, Germany, Italy, Spain and UK. Europe: Includes the following 49 countries with the exception of Europe Core countries: i) All EU members states, ii) EEA members Iceland and Norway, iii) EU candidate countries Croatia, Former Yugoslav Republic of Macedonia, and Turkey, and iv) each of the following other European countries: Albania, Andorra, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Liechtenstein, Moldova, Monaco, Montenegro, Russia, San Marino, Serbia, Switzerland, Ukraine and Vatican City State. EU accession: Includes, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovakia, Slovenia. Latin America: Includes, Argentina, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guadeloupe, Guatemala, Honduras, Jamaica, Martinique, Mexico, Panama, Peru, Puerto Rico, Uruguay and Venezuela Middle East & Africa: Includes, Middle East & Africa includes the following countries: Afghanistan, Algeria, Bahrain, Egypt, Iran, Israel, Ivory Coast, Jordan, Kenya, Lebanon, Morocco, Namibia, Nigeria, Oman, Reunion, Saudi Arabia, South Africa, Tanzania, Tunisia, Turkey, United Arab Emirates North America: Includes USA and Canada SE Asia & W Pacific: Includes, Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Korea, Laos, Malaysia, New Zealand, Pakistan, Philippines, Singapore, Taiwan, Thailand, Vietnam CMR International Performance Metrics Program / Source Global Clinical Performance Metrics Program Latin America 2000 3% 2006 7% Based on studies from a consistent cohort of 23 companies where patient enrolment was completed in each year range. Percentages may not necessarily add up to 100% as some study locations may be unassigned. SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS

Terms of Use and Disclaimer The materials contained in these slides may be used for your own use in presenting at conferences and meetings or for inclusion in reports provided that you acknowledge the source of the materials and include the following statement: “2008 © Thomson Reuters. Some of the materials and/or data in this [report, presentation, paper etc] are reproduced under a license from Thomson Reuters. You may not copy or re-distribute these materials in whole or in part without the written consent of Thomson Reuters”. Charts, graphs, and illustrations contained in these slides may not be decompiled, reverse engineered, or disassembled. The copyright and other intellectual property rights in these slides is owned by Thomson Reuters or its licensors. Except for the license set out in these Terms of Use, Thomson Reuters neither assigns any rights nor grants any licenses or rights in respect of these slides to you and any use of these slides other than in accordance with these Terms of Use is subject to Thomson Reuters’ prior written consent. For additional permissions, please contact: [contact email] THOMSON REUTERS MAKES NO WARRANTY OR REPRESENTATION AS TO THE ACCURACY, COMPLETENESS OR CORRECTNESS OF ANY MATERIALS CONTAINED WITHIN THESE SLIDES OR THAT ALL ERRORS IN THE SLIDES OR THE MATERIALS CONTAINED WITHIN THESE SLIDES WILL BE CORRECTED. THOMSON REUTERS IS AN INFORMATION PROVIDER AND DOES NOT PROVIDE LEGAL, FINANCIAL OR OTHER PROFESSIONAL ADVICE. THE MATERIALS CONTAINED IN THESE SLIDES ARE FOR GENERAL INFORMATION PURPOSES ONLY, ARE NOT INTENDED TO CONSTITUTE LEGAL OR OTHER PROFESSIONAL ADVICE, AND SHOULD NOT BE RELIED ON OR TREATED AS A SUBSTITUTE FOR SPECIFIC ADVICE RELEVANT TO PARTICULAR CIRCUMSTANCES. THOMSON REUTERS SHALL NOT BE LIABLE FOR ANY LOSS THAT MAY ARISE FROM ANY RELIANCE BY YOU, YOUR EMPLOYER OR CLIENT, OR ANY OTHER THIRD PARTY, ON THE MATERIALS CONTAINED IN THESE SLIDES. THOMSON REUTERS WILL NOT BE LIABLE IN CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE FOR ANY INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL LOSS OR DAMAGE ARISING OUT OF OR IN CONNECTION WITH THESE TERMS OF USE OR YOUR USE OF THE SLIDES, HOWEVER SUCH INDIRECT LOSS OR DAMAGE MAY ARISE. You shall not assign, sub-licence or delegate any of your rights or obligations under these Terms of Use without the prior written consent of Thomson Reuters; any assignment, sub-licensing or delegation in breach of these Terms of Use shall be null and void. If any provision of these Terms of Use are determined to be illegal or unenforceable by any court of competent jurisdiction it shall be deemed to have been deleted without affecting the remaining provisions. These Terms of Use will be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania. You hereby irrevocably submit to the exclusive jurisdiction of the federal and state courts located in Philadelphia, PA, USA.